Nor-epinephrine Versus Midodrine/Octreotide in Patients With Hepatorenal Syndrome

Nor-epinephrine Versus Midodrine/Octreotide in Patients With Hepatorenal Acute Kidney Injury

NCT04522297•National Hepatology & Tropical Medicine Research Institute

Summary

Hepatorenal syndrome is a functional renal impairment occurring in cirrhotic patients . It develops secondary to splanchnic arterial vasodilatation which decreases the effective blood volume, activate the renin-angiotensin-aldosterone system, and stimulate of sympathetic nervous system.This study aims to compare the efficacy of nor-epinephrine versus midodrine/ octreotide, together with intravenous albumin on renal functions of patients with hepatorenal acute kidney injury.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Both sexes aged 18 years or older having cirrhosis, ascites, and a diagnosis of HRS-AKI based on the 2015 International Club of Ascites (ICA) diagnostic criteria

Exclusion Criteria

•Serum creatinine (sCr) \>7 mg/dL Hypotension (mean arterial pressure (MAP) \<70 mm Hg) or sepsis. Recent treatment with vasopressors. Patients with severe cardiovascular disease Known allergy to study medications

Locations (1)

The National Hepatology and Tropical Research medicine institute

Cairo, Egypt

Key Dates

Start Date

April 15, 2018

Primary Completion Date

January 23, 2020

Completion Date

January 23, 2020

Last Updated

August 21, 2020

Enrollment

ACTUAL participants

Conditions

Hepato-Renal Syndrome

Interventions

Midodrine/Octreotide

DRUG

Nor-epinephrine

DRUG

MRI to Assess the Effect of Terlipressin in Patients With Acute Hepatorenal Syndrome (HRS-AKI)

NCT03483272

Hepato-Renal SyndromePortal Hypertension+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 21, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions